CN103739677A - 一种抑制核因子-κB多肽及其应用 - Google Patents
一种抑制核因子-κB多肽及其应用 Download PDFInfo
- Publication number
- CN103739677A CN103739677A CN201310748610.5A CN201310748610A CN103739677A CN 103739677 A CN103739677 A CN 103739677A CN 201310748610 A CN201310748610 A CN 201310748610A CN 103739677 A CN103739677 A CN 103739677A
- Authority
- CN
- China
- Prior art keywords
- nuclear factor
- polypeptide
- kappa
- arthritis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
- 102000003945 NF-kappa B Human genes 0.000 title claims abstract description 38
- 108010057466 NF-kappa B Proteins 0.000 title claims abstract description 38
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 36
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 36
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 22
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims description 4
- 239000002547 new drug Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 21
- 206010003246 arthritis Diseases 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010039361 Sacroiliitis Diseases 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000003423 ankle Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710115512 Nuclear receptor coactivator 5 Proteins 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- 206010048873 Traumatic arthritis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- PBQVHWFDMNCCIH-KNJAVFAGSA-N (4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine;n-(4-hydroxyphenyl)acetamide;phosphoric acid;hydrochloride Chemical compound Cl.OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C([C@H]1C(N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC PBQVHWFDMNCCIH-KNJAVFAGSA-N 0.000 description 1
- JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- JIVJQYNNAYFXDG-LKXGYXEUSA-N Cys-Thr-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JIVJQYNNAYFXDG-LKXGYXEUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- NADWTMLCUDMDQI-ACZMJKKPSA-N Glu-Asp-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N NADWTMLCUDMDQI-ACZMJKKPSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- YHFPHRUWZMEOIX-CYDGBPFRSA-N Ile-Val-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)N YHFPHRUWZMEOIX-CYDGBPFRSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 101000974353 Mus musculus Nuclear receptor coactivator 5 Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310748610.5A CN103739677B (zh) | 2013-12-31 | 2013-12-31 | 一种抑制核因子-κB多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310748610.5A CN103739677B (zh) | 2013-12-31 | 2013-12-31 | 一种抑制核因子-κB多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103739677A true CN103739677A (zh) | 2014-04-23 |
CN103739677B CN103739677B (zh) | 2015-09-09 |
Family
ID=50496761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310748610.5A Expired - Fee Related CN103739677B (zh) | 2013-12-31 | 2013-12-31 | 一种抑制核因子-κB多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103739677B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105585616A (zh) * | 2016-02-01 | 2016-05-18 | 苏州普罗达生物科技有限公司 | 核因子-κB多肽抑制剂及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103265619A (zh) * | 2013-05-30 | 2013-08-28 | 苏州普罗达生物科技有限公司 | 肿瘤坏死因子-α多肽抑制剂及其应用 |
CN103288922A (zh) * | 2013-05-30 | 2013-09-11 | 苏州普罗达生物科技有限公司 | 肿瘤坏死因子-α多肽抑制剂及其应用 |
CN103285373A (zh) * | 2013-05-30 | 2013-09-11 | 苏州普罗达生物科技有限公司 | 肿瘤坏死因子-α多肽抑制剂制备及其应用 |
-
2013
- 2013-12-31 CN CN201310748610.5A patent/CN103739677B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103265619A (zh) * | 2013-05-30 | 2013-08-28 | 苏州普罗达生物科技有限公司 | 肿瘤坏死因子-α多肽抑制剂及其应用 |
CN103288922A (zh) * | 2013-05-30 | 2013-09-11 | 苏州普罗达生物科技有限公司 | 肿瘤坏死因子-α多肽抑制剂及其应用 |
CN103285373A (zh) * | 2013-05-30 | 2013-09-11 | 苏州普罗达生物科技有限公司 | 肿瘤坏死因子-α多肽抑制剂制备及其应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105585616A (zh) * | 2016-02-01 | 2016-05-18 | 苏州普罗达生物科技有限公司 | 核因子-κB多肽抑制剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103739677B (zh) | 2015-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104127859B (zh) | 多肽在制备治疗或预防类风湿性关节炎药物中的应用 | |
CN103739670A (zh) | 一种聚乙二醇修饰的抑制肿瘤坏死因子-α多肽及其应用 | |
CN103772489B (zh) | 核因子-kb多肽抑制剂5及其应用 | |
CN103772491B (zh) | 核因子-kb多肽抑制剂3及其应用 | |
CN103819540B (zh) | 核因子-kb多肽抑制剂及其应用 | |
CN103739669B (zh) | 一种抑制白介素-6多肽及其应用 | |
CN103739671B (zh) | 一种聚乙二醇修饰的抑制核因子-κB多肽及其应用 | |
CN103739677B (zh) | 一种抑制核因子-κB多肽及其应用 | |
CN103254291B (zh) | 肿瘤坏死因子-α多肽抑制剂及其应用 | |
CN103772492B (zh) | 核因子-kb多肽抑制剂4及其应用 | |
CN103285373A (zh) | 肿瘤坏死因子-α多肽抑制剂制备及其应用 | |
CN103739673B (zh) | 一种聚乙二醇修饰的抑制白介素-6多肽及其应用 | |
CN103265619A (zh) | 肿瘤坏死因子-α多肽抑制剂及其应用 | |
CN103893161A (zh) | 丁香酸-(4-羟基-3,5-二甲氧基苯甲酸)在制备预防和治疗类风湿关节炎中的应用 | |
CN105061583A (zh) | 外周白介素35多肽及其应用 | |
CN103923185A (zh) | 白介素-6多肽抑制剂及其应用 | |
CN103923183A (zh) | 白介素-6多肽抑制剂及其应用 | |
CN103288921A (zh) | 血管内皮生长因子受体2酪氨酸激酶多肽抑制剂及其应用 | |
CN103288922A (zh) | 肿瘤坏死因子-α多肽抑制剂及其应用 | |
CN103923182A (zh) | 白介素-6多肽抑制剂及其应用 | |
CN103923180A (zh) | 白介素-6多肽抑制剂及其应用 | |
CN103751169A (zh) | 3’-甲氧基苯甲基-3,5-二甲氧基-4-(3’-甲氧基苄氧基)苯甲酸酯在制备治疗或预防类风湿关节炎中的应用 | |
CN110101845B (zh) | 鸢尾素在制备防治术后认知功能障碍以及血脑屏障受损所介导脑病的药物中的应用 | |
CN103751168A (zh) | 3’-甲氧基苯甲基-4-羟基-3,5-二甲氧基-苯甲酸酯在制备治疗或预防类风湿关节炎中的应用 | |
CN105504022A (zh) | 核因子-κB多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HEBEI WANTONG JINNIU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LUO RUIXUE Effective date: 20150813 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Hao Qiushi Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LUO RUIXUE TO: HAO QIUSHI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150813 Address after: Xinghua Road in Dingzhou city in Hebei province Baoding City, No. 25, 073000 Applicant after: Hebei Wan Tong Taurus pharmaceutcal corporation, Ltd Address before: 639 No. 211198 Jiangsu province Nanjing city Jiangning District University City longmian Road Applicant before: Luo Ruixue |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150909 Termination date: 20161231 |